Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
brenetafusp + bevacizumab
- Development stage
- Unknown
- Lead developer
- Immunocore
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Brenetafusp is an ImmTAC (Immune mobilizing monoclonal TCRs Against Cancer) bispecific biologic targeting PRAME, under development for the treatment of ovarian cancer. It has shown clinical activity as monotherapy and in combination with chemotherapy in heavily pre-treated, platinum-resistant ovarian cancer patients. Bevacizumab is a recombinant humanized monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), thereby blocking angiogenesis and reducing tumor blood supply. Bevacizumab is approved for use in multiple cancers including colorectal, lung, glioblastoma, renal cell carcinoma, cervical cancer, and ovarian cancer. The combination of brenetafusp and bevacizumab represents a multi-modal approach targeting both tumor antigens (via T-cell redirection) and tumor vasculature (via VEGF inhibition)[3][4][5][7].
- Other names
- none
02
Targets
VEGFA (Vascular endothelial growth factor A)HLA-A*02 (Human leukocyte antigen A*02 complexed peptide)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on brenetafusp + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on brenetafusp + bevacizumab.